← All stocks

Nurix Therapeutics, Inc.

NRIX Mostly scheduled

CIK 0001549595 #1793 in the set updated 17 Sep 2026

Bought (120 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$13.90M

$2.89M on a plan · $10.80M straight out of an exercise

Sold at will

$210.74K

22 of 191 sales

Net

−$13.90M

−$210.74K against sales at will

By person

12 insiders · 196 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Ring Christine

Chief Legal Officer

—

$5.97M (78) scheduled

−$5.97M

9,110

0.0088%

$242.67K

+125.0%

van Houte Hans

Chief Financial Officer

—

$4.62M (45) scheduled

−$4.62M

40,166

0.0387%

$1.07M

—

Beaurang Pierre

Chief Business Officer

—

$1.84M (21) scheduled

−$1.84M

120,996

0.1166%

$3.22M

+3.7%

Hansen Gwenn

Chief Scientific Officer

—

$1.45M (42) scheduled

−$1.45M

117,227

0.1130%

$3.12M

+2,451%

Wolff Stefani

EVP and COO

—

$22.34K (5)

−$22.34K

6,113

0.0059%

$162.84K

+96.9%

Third Rock Ventures III, L.P. entity

10% owner

—

3,509,348

3.38%

$93.48M

+3,943%

COLUMN GROUP L P entity

10% owner

—

2,080,607

2.00%

$55.42M

—

Redmile Group, LLC entity

10% owner

—

1,176,470

1.13%

$31.34M

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

784,313

0.7557%

$20.89M

—

Tjian Robert

Director

—

124,999

0.1204%

$3.33M

+275.0%

GREGORY JULIA P

Director

—

10,750

0.0104%

$286.35K

—

Kunkel Lori Anne

Director

—

0.0000%

$0.00

−100.0%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 242

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 26

Sales straight out of an exercise 143

Sales at will 22

Transactions with no price 0

Shares from compensation/vesting 32,280,499

Sales filed before the plan box existed 12

History held since 29 Jul 2020